Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.

NCT01678872 · ClinicalTrials.gov registry record · Phase 1

A Follow-up Study to Evaluate the Safety of RetinoStat® in Patients With Age-Related Macular Degeneration

A Phase 1 study of Age-related Macular Degeneration, sponsored by Oxford BioMedica.

Active
Registry status
Phase 1
Development phase
18
Enrollment target
3
Study locations

NCT01678872: Active Phase 1 study of Age-related Macular Degeneration, sponsored by Oxford BioMedica.

NCT01678872 is a Phase 1 study of Age-related Macular Degeneration that is active but no longer recruiting, run by Oxford BioMedica. The registered enrollment target is 18 participants, below the 1,508-participant average among 74 other Age-related Macular Degeneration trials with a reported enrollment target (99% lower). The trial reports 3 study locations across 3 states. According to ClinicalTrials.gov, the official US trial registry.

View on ClinicalTrials.gov ↗

View your shortlist →

The verdict

NCT01678872, a Phase 1 study of Age-related Macular Degeneration, is active but no longer recruiting, sponsored by Oxford BioMedica.

ACTIVE NOT RECRUITING
Registry status
Phase 1
Development phase
18 participants
Enrollment target
3
Study locations

Study Summary

The purpose of this study is to examine the long term safety of an experimental gene transfer agent, RetinoStat®, designed to treat neovascular age-related macular degeneration.

Primary Outcome

The number of subjects with treatment emergent adverse events.

Conditions Studied

Age-related Macular Degeneration

Interventions

  • DRUG RetinoStat

Study Locations (3)

Iowa

  • University of Iowa Hospitals & Clinics - Iowa City

Maryland

  • John Hopkins University Hospital - Baltimore

Oregon

  • Oregon Health & Science University - Portland

Trial Details

FieldValue
Enrollment Target 18 participants
Start Date 2012-08
Est. Completion 2029-03
Phase Phase 1
Oxford BioMedica

6 total trials

What the registry record for NCT01678872 still lists

NCT01678872 is an interventional study that assigns participants to a tested intervention. The registry caps enrollment at 18 participants, a relatively small participant target, below the 1,508-participant average among 74 other Age-related Macular Degeneration trials with a reported enrollment target (99% lower).

The record links to 1 condition, with Age-related Macular Degeneration appearing as the primary indexed condition, and to 1 intervention - of which RetinoStat is the first listed.

NCT01678872 reports a single indexed study location in Iowa, Maryland, Oregon.

Frequently Asked Questions

What is clinical trial NCT01678872 about?

NCT01678872 is a clinical study titled "A Follow-up Study to Evaluate the Safety of RetinoStat® in Patients With Age-Related Macular Degeneration". The purpose of this study is to examine the long term safety of an experimental gene transfer agent, RetinoStat®, designed to treat neovascular age-related macular degeneration.

What is the current status of trial NCT01678872?

This trial is currently active not recruiting. It is a Phase 1 study. The enrollment target is 18 participants. The study started on 2012-08. Estimated completion is 2029-03.

What conditions does trial NCT01678872 study?

This clinical trial studies the following conditions: Age-related Macular Degeneration.

What interventions are being tested in trial NCT01678872?

The interventions under investigation include: RetinoStat (DRUG).

Who is sponsoring clinical trial NCT01678872?

This trial is sponsored by Oxford BioMedica, which has 6 total clinical trials registered on ClinicalTrials.gov.

Where is trial NCT01678872 being conducted?

This trial has 3 study locations across Iowa, Maryland, Oregon. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.

Learn More About Clinical Trials

Similar trials for Age-related Macular Degeneration

Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.

Where NCT01678872's enrollment target sits among peer trials

18 68th of 74 higher than 7 of 74 other Age-related Macular Degeneration trials

participants (enrollment target), bucketed by value

Each bar is a band; taller bars hold more other Age-related Macular Degeneration trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.

Source ClinicalTrials.gov registry export · 2026-08-08

Nationwide trials with similar profiles

Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.

Similar enrollment target

  • NCT01245179 · 18 participants · Phase 1

    Study of Panobinostat (LBH589) in Patients With Sickle Cell Disease

  • NCT01999361 · 18 participants · NA

    Prevention of de Novo Allosensitization in Islet Transplant Recipients Following Complete Graft Loss

  • NCT02359825 · 18 participants · Phase 1

    Nerve Repair Using Hydrophilic Polymers to Promote Immediate Fusion of Severed Axons and Swift Return of Function

  • NCT02870244 · 18 participants · Phase 1

    Adoptive T Cell Immunotherapy for Advanced Melanoma Using Engineered Lymphocytes

Similar registry start date

  • NCT05988463 · started 2027-01-01 · Phase 1

    Dose-Escalation Study of Artesunate Patients With IPF

  • NCT07219706 · started 2026-12-10 · NA

    Dietary Fiber and Time Restricted Eating

  • NCT02831335 · started 2026-12-01

    Technical Development of Multi-Parametric Renocerebral MRI

  • NCT05962346 · started 2026-12 · NA

    Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia

Related registry views

Source: ClinicalTrials.gov NCT01678872, the US trial registry maintained by the National Library of Medicine. NCT01678872 (small enrollment · single site footprint · active not recruiting) retrieved and formatted by PlainTrial, see methodology.